KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/16618717

Cancer Res. 2006 Apr 15 66 8 3992-5

Download in:

View as

Triples

General Info

PMID
16618717